Clinical Trial Detail

NCT ID NCT01859026
Title A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

lung non-small cell carcinoma

lung cancer

Therapies

Binimetinib + Erlotinib

Age Groups: adult senior

No variant requirements are available.